Anti-Cystatin C Magnetic Beads Immunoprecipitation (IP) Kit

Temporarily not available outside of China.
Price:
Size:
Number:

Anti-Cystatin C Magnetic Beads-IP Kit Product Components

Components Storage
Anti-Cystatin C Magnetic Beads1,3 2-8℃ for 12 months
NP40 Cell Lysis Buffer2 -20℃ for 12 months
5×TBST(pH7.4)  
1×TBST(pH7.4)  
ddH2O  
Alkaline Elution Buffer 2-8℃ for 12 months
Acidity Elution Buffer 2-8℃ for 12 months
Neutralization Buffer 2-8℃ for 12 months

【1】The IP KIT contains anti-Cystatin C magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).

【2】Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.

【3】Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.

Anti-Cystatin C Magnetic Beads-IP Kit Product Description

The Anti-Cystatin C magnetic Beads, conjugated with Anti-Cystatin C antibody, are used for immuneprecipitation (IP) of Cystatin C proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing Cystatin C proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound Cystatin C proteins are dissociated from the magnetic beads using an elution buffer.

Anti-Cystatin C Magnetic Beads-IP Kit Antibody Information

Antibody
Anti-Cystatin C Antibody(50239-RP02)
Immunogen
Recombinant Mouse CST3 protein (Catalog#50239-M08H)
Species Reactivity
Mouse CST3 / Cystatin-C
Source
Polyclonal Mouse Rabbit IgG
Preparation
Produced in rabbits immunized with purified, recombinant Mouse CST3 (rM CST3; Catalog#50239-M08H; NP_034106.2; Met 1-Ala 140). CST3 specific IgG was purified by mouse CST3 affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification

Anti-Cystatin C Magnetic Beads Immunoprecipitation (IP) Kit: Synonyms

Anti-CysCALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit

Cystatin C Background Information

Cystatin C, also known as Cystatin-3 (CST3) is a secreted type 2 cysteine protease inhibitor synthesized in all nucleated cells, has been proposed as a replacement for serum creatinine for the assessment of renal function, particularly to detect small reductions in glomerular filtration rate. The mature, active form of human cystatin C is a single non-glycosylated polypeptide chain consisting of 12 amino acid residues, with a molecular mass of 13,343-13,359 Da, and containing four characteristic disulfide-paired cysteine residues. Cystatin C is a low-molecular-weight protein which has been proposed as a marker of renal function that could replace creatinine. Indeed, the concentration of Cystatin C is mainly determined by glomerular filtration and is particularly of interest in clinical settings where the relationship between creatinine production and muscle mass impairs the clinical performance of creatinine. Since the last decade, numerous studies have evaluated its potential use in measuring renal function in various populations. More recently, other potential developments for its clinical use have emerged. In almost all the clinical studies, Cystatin C demonstrated a better diagnostic accuracy than serum creatinine in discriminating normal from impaired kidney function, but controversial results have been obtained by comparing this protein with other indices of kidney disease, especially serum creatinine-based equations, such as early atherosclerosis, Alzheimer's dementia, vascular aneurysms, hyperhomocysteinaemia and other neurodegenerative diseases. Cystatin C could be a useful clinical tool to identify HIV-infected persons. In addition, its expression is up-regulated in malignance of certain tumor progression.
Full Name
cystatin C
References
  • Mares J, et al. (2003) Use of cystatin C determination in clinical diagnostics. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 147(2): 177-80.
  • Mussap M, et al. (2004) Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 41(5-6): 467-550.
  • Sronie-Vivien S, et al. (2008) Cystatin C: current position and future prospects. Clin Chem Lab Med. 46(12): 1664-86.
  • Taglieri N, et al. (2009) Cystatin C and cardiovascular risk. Clin Chem. 55(11): 1932-43.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.